 |
| Contact us |
|
| For media professionals: |
This contact information is for media professionals only. If you are not a member of the news media, please contact us via the phone number or email link at the bottom of the page.
|
|
| U.S. Communications: |
Lisa Buffington
(908) 981-6569
US.media-relations@sanofi-aventis.com
sanofi-aventis U.S.
55 Corporate Drive
Bridgewater, NJ 08807
Tel: 800-981-2491
|
| Via email |
|
|
|
|
| Last update: July 29, 2009 |
|
| Latest News |
|
| June 17, 2010 |
| Jevtana® (cabazitaxel) Injection Approved by U.S. FDA After Priority Review |
|
|
|
|
| May 05, 2010 |
| Sanofi-aventis Joins the Massachusetts Life Sciences Center’s Corporate Consortium Program to Support Innovation in Research & Development |
|
|
|
|
| April 29, 2010 |
| Q1 2010: A good first quarter |
|
|
|
|
| March 12, 2010 |
| Sanofi-aventis and Bristol-Myers Squibb Announce Important Updates to PLAVIX® U.S. Prescribing Information |
|
|
|
|
| March 11, 2010 |
| Sanofi-aventis Successfully Completes the Acquisition of Chattem, Inc. |
|
|
|
|
|
|
